登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301366 证券简称：一博科技 公告编号：2025-039 深圳市一博科技股份有限公司 第三届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 深圳市一博科技股份有限公司（以下简称公司）第三届董事会第六次会议通知于2025年9月18日以微 信、电子邮件等方式向全体董事及高级管理人员发出，会议于2025年9月24日以腾讯会议通讯表决方式 召开，本次会议由董事长汤昌茂先生主持，会议应出席董事8名，实际出席董事8名，全体董事以通讯方 式参会，公司部分高级管理人员列席了会议。本次会议的召集、召开及表决程序符合《中华人民共和国 公司法》《中华人民共和国证券法》《上市公司治理准则》等有关法律、行政法规、规范性文件（以下 统称法律法规）和《深圳市一博科技股份有限公司章程》（以下简称《公司章程》）的规定，会议决议 合法有效。 二、董事会会议审议情况 （一）会议以8票同意，0票反对，0票弃权，0票回避，审议通过了《关于使用部分暂时闲置募集资金及 自有资金进行现金管理的议 ...

Group 1 - The core viewpoint of the article highlights that Yibo Technology (SZ 301366) held its sixth board meeting on September 24, 2025, via Tencent Meeting to discuss the proposal for using excess raised funds to permanently supplement working capital [1] - For the fiscal year 2024, Yibo Technology's revenue composition is as follows: Network Communication 29.42%, Industrial Control 28.67%, Integrated Circuits 11.72%, Medical Electronics 9.03%, Artificial Intelligence 8.97%, and Smart Transportation 5.42% [1] - As of the report date, Yibo Technology has a market capitalization of 8.3 billion yuan [1] Group 2 - The article also notes that on the anniversary of the "9·24" event, the total market capitalization of A-shares has surpassed 116 trillion yuan, indicating significant changes in the Chinese capital market [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603275 证券简称：众辰科技 公告编号：2025-061 上海众辰电子科技股份有限公司 关于召开2025年半年度业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025年09月30日（星期二）09:00-10:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于2025年09月23日（星期二）至09月29日（星期一）16:00前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司邮箱xuwenjun@zoncn.cn进行提问。公司将在说明会上对投资者普遍关 注的问题进行回答。 上海众辰电子科技股份有限公司（以下简称"公司"）已于2025年8月26日发布公司2025年半年度报告， 为便于广大投资者更全面深入地了解公司2025年半年度经营成果、财务状况，公司计划于2025年09月30 日（星期二）09:0 ...

Meeting Overview - The second supervisory board meeting of Jiangsu Huasheng Lithium Battery Materials Co., Ltd. was held on August 26, 2025, combining on-site and remote participation [1] - The meeting was chaired by the chairman of the supervisory board, Zhou Chao, and all resolutions made were deemed legal and effective according to relevant laws and regulations [1] Financial Reporting - The supervisory board approved the company's 2025 semi-annual report, confirming that the preparation and review processes complied with relevant laws and internal regulations, accurately reflecting the company's financial status and operational results for the first half of 2025 [1][2] - The supervisory board ensured that there were no violations of confidentiality during the report preparation process and that the report contained no false statements or significant omissions [1] Fund Management - The supervisory board confirmed that the management of raised funds for the first half of 2025 complied with relevant laws and regulations, with funds stored in dedicated accounts and used for specified purposes [2] - The company disclosed the actual use of raised funds accurately and timely, fulfilling its information disclosure obligations [2] Asset Impairment - The supervisory board agreed on the provision for asset impairment, stating that it complied with accounting standards and accurately reflected the company's financial condition and asset value [3] - The decision-making process for the impairment provision was deemed compliant with legal and regulatory requirements [3] Foreign Exchange Derivatives - The supervisory board approved the company's plan to engage in foreign exchange derivative transactions up to $25 million or equivalent in other currencies to mitigate foreign exchange risk [4] - The company established relevant approval and internal control systems for these transactions [4] Use of Additional Funds - The supervisory board approved the use of RMB 237 million of excess raised funds to permanently supplement working capital, enhancing fund utilization efficiency and reducing financial costs [4][5] - This decision aligns with the company's development strategy and benefits all shareholders [5] Governance Changes - The supervisory board agreed to cancel the supervisory board and transfer its powers to the audit committee of the board of directors to improve corporate governance and operational efficiency [5][6] - The legal representative of the company will change from the chairman to the general manager, with corresponding amendments to the company's articles of association [6] - The supervisory board also approved revisions to certain governance documents in line with updated legal and regulatory requirements [6]

Group 1 - The company announced that it will hold its second extraordinary general meeting of shareholders in 2025 on September 12 [1] - The agenda for the meeting includes the proposal to use part of the raised funds to permanently supplement working capital [1]

Group 1 - The core point of the announcement is the decision by Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. to use part of the raised funds to permanently supplement its working capital, amounting to RMB 363.87 million [1][2]. - The decision was made during the third meeting of the fourth supervisory board held on August 4, 2025, with all three supervisors present, ensuring compliance with relevant laws and regulations [1][2]. - The use of the funds is aimed at reducing financial costs, enhancing operational efficiency, and improving profitability, while ensuring that it does not affect the construction of investment projects or the company's daily operations [1][2]. Group 2 - The proposal to use the raised funds requires approval from the company's shareholders' meeting, with a voting result of 3 votes in favor, 0 against, and 0 abstentions [2]. - The decision aligns with the regulations set forth in the "Regulations on the Supervision of Raised Funds by Listed Companies" and other relevant guidelines, ensuring no harm to the interests of the company or minority shareholders [1].

Group 1 - The company held its sixth meeting of the fourth Supervisory Board on June 13, 2025, with all three supervisors present, and the meeting was deemed legally valid [1] - The Supervisory Board approved the use of self-raised funds amounting to 22.3779 million yuan for pre-investment in fundraising projects and payment of part of the issuance costs totaling 4.4262 million yuan, which complies with relevant regulations [1] - The company plans to use no more than 300 million yuan of idle raised funds for cash management, which is expected to enhance fund utilization efficiency and provide better returns for shareholders [2][3] Group 2 - The company intends to temporarily supplement working capital with up to 15 million yuan of idle raised funds, which aligns with regulatory requirements and aims to improve fund efficiency [3] - The Supervisory Board also approved the use of part of the excess raised funds for permanent working capital supplementation, which is expected to lower financial costs and enhance fund utilization [4]

Group 1 - The company held its 19th meeting of the 4th Supervisory Board on May 8, 2025, with all three supervisors present, and the meeting was chaired by Mr. Wang Qiang [1][2] - The Supervisory Board unanimously agreed to use part of the raised funds to permanently supplement working capital, which complies with relevant regulations and does not harm the interests of shareholders, especially minority shareholders [1][2] - The resolution will be submitted to the company's shareholders' meeting for further approval [2]